Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Key Stats

• Today's Range: $21.16 to $23.30
• 50-Day Range: $18.51 to $30.49
• 52-Week Range: $18.20 to $53.88
• Volume: 746,294 shs
• Average Volume: 78,156 shs
• Market Capitalization: $785.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.17
• Consensus Rating: Buy

Oruka Therapeutics Stock Analysis - MarketRank™

Oruka Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 239th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Oruka Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Oruka Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oruka Therapeutics are expected to grow in the coming year, from ($3.21) to ($2.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oruka Therapeutics is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oruka Therapeutics is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oruka Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ORKA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oruka Therapeutics does not currently pay a dividend.

Dividend Growth

Oruka Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ORKA.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.11

News Sentiment

Oruka Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Oruka Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oruka Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.67% of the stock of Oruka Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.44% of the stock of Oruka Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORKA Stock Analysis - Frequently Asked Questions

How have ORKA shares performed this year?

Oruka Therapeutics' stock was trading at $27.99 at the beginning of the year. Since then, ORKA shares have decreased by 19.8% and is now trading at $22.45.
View the best growth stocks for 2024 here.

Who are Oruka Therapeutics' major shareholders?

Top institutional investors of Oruka Therapeutics include FMR LLC (386.97%), RTW Investments LP (152.95%), Franklin Resources Inc. (2.06%) and Braidwell LP (42.69%).

How do I buy shares of Oruka Therapeutics?

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Oruka Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oruka Therapeutics investors own include Astria Therapeutics (ATXS), Aldeyra Therapeutics (ALDX), Black Diamond Therapeutics (BDTX), Energy Transfer (ET), Heron Therapeutics (HRTX), Skye Bioscience (SKYE) and Skye Bioscience (SKYE).

Company Calendar

• Today: 12/17/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ORKA
• Previous Symbol: NASDAQ:ORKA
• CUSIP: N/A
• CIK: 907654
• Web: www.arcabio.com
• Phone: 720-940-2100
• Fax: 720-208-9261
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $43.17
• High Stock Price Target: $49.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +87.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,340,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.96%
• Return on Assets: -21.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.89
• Quick Ratio: 22.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.72 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 34,999,000
• Free Float: 27,065,000
• Market Cap: $805.33 million
• Optionable: N/A
• Beta: 0.78